Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper Sells 10,000 Shares

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $70,873,516.56. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Thermo Fisher Scientific Stock Up 1.1 %

TMO stock traded up $6.39 on Wednesday, hitting $575.11. 1,171,942 shares of the company's stock were exchanged, compared to its average volume of 1,549,559. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The firm has a 50 day moving average price of $575.03 and a two-hundred day moving average price of $531.97. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The stock has a market cap of $219.53 billion, a P/E ratio of 36.89, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is presently 10.01%.

Institutional Trading of Thermo Fisher Scientific

Large investors have recently added to or reduced their stakes in the company. Northwest Financial Advisors purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $29,000. True Wealth Design LLC boosted its stake in shares of Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company's stock worth $29,000 after buying an additional 51 shares during the last quarter. LifeSteps Financial Inc. purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. Pineridge Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $39,000. Finally, Cape Investment Advisory Inc. boosted its stake in shares of Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company's stock worth $40,000 after buying an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TMO shares. Raymond James lifted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a report on Thursday, April 25th. Sanford C. Bernstein reissued a "market perform" rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. Finally, Evercore ISI raised their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a research note on Thursday, April 4th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.